Cyxone AB announces promising T20K/KORa combination therapy efficacy in preclinical therapeutic model of MS

Cyxone AB (CYXO), a clinical-stage company developing transformative therapies in the autoimmune area to improve patient outcomes, today announced results from its ongoing collaboration with Medical University of Vienna.

Biotech company Cyxone is developing T20K, a drug candidate with first-in-class potential for the treatment of multiple sclerosis. Cyxone and its research partner, the Medical University of Vienna, announced pre-clinical data further supporting T20K as a treatment for MS in combination with a kappa opioid receptor agonist (KORa).

Previously Cyxone announced efficacy of T20K/KORa drug combination in a preventative model: a model where the drug is administered before disease onset preventing it from establishing. In a therapeutic model, the research animals develop disease symptoms over several days before the drugs are administered. The therapeutic model represents a higher bar for efficacy than a preventative model in MS. When T20K/KOR agonist combination was administered in the therapeutic model the efficacy was shown to be dose dependent and synergistic. This supports the concept of T20K/KORa combination therapy as a viable therapy for MS and warrants further investigation.

“We are excited to see the strong preclinical results supporting our patent application and the hypothesis for T20K/KORa combination therapy. With this combination we can explore a novel therapy for both early and more advanced MS potentially expanding the scope of treatment options for MS,” comments Tara Heitner, CEO, Cyxone.

“The kappa opioid receptor has recently been established as a promising target for neurodegenerative diseases and appears to be involved in rebuilding of damaged nerve cell sheath. Triggered by data from our laboratories that T20K acts synergistically with known kappa opioid receptor drugs, we have now started to explore the opportunity to utilize T20Ks potential as immunosuppressive and myelin repair compound,” says Christian Gruber from the Medical University of Vienna.

Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se. For more information, please visit www.cyxone.com